| Active substance |
Medroxyprogesterone |
| Also known as |
MPA |
| Blood pressure |
No significant effect |
| Chemical name |
Medroxyprogesterone acetate |
| Dosage (medical) |
Oral: 2.5-10 mg daily, Injectable: 150 mg every 3 months |
| Dosage (sports) |
Not applicable |
| Effects |
Prevents ovulation, alters cervical mucus and endometrial lining |
| Formula |
C24H34O4 |
| Half-life |
Approximately 50 days (injectable form), 17 to 24 hours (oral form) |
| Hepatotoxicity |
Low |
| Lab Test |
Hormone levels monitoring |
| Main action |
Progestogenic agent |
| Side effects |
Weight gain, headache, nausea, menstrual irregularities, depression |
| Storage conditions |
Store at room temperature, protect from light |
| Strength |
150 mg/mL |
| Substance class |
Progestin |
| Trade name |
Depo-Provera, Provera |
| Use in sports |
Not typically used in sports |
| Water Retention |
Minimal |
| Manufacturer |
Pfizer Ltd. |
| Packing |
1 injection/pack |
